Development and characterization of chitosan coated poly-(e{open}-caprolactone) nanoparticulate system for effective immunization against influenza

Vaccine

Volumn 29, Issue 48, 2011, Pages 9026-9037

  Gupta, Nand Kishore ^a   Tomar, Priti ^a   Sharma, Vikas ^a   Dixit, Vinod Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Chitosan; HA protein; Immunity, Antigen integrity; Nanoparticles; Nasal carrier adjuvants

Indexed keywords

CHITOSAN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 4; NANOPARTICLE; POLYCAPROLACTONE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DIFFUSION; EMULSION; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A; LUNG LAVAGE; MOLECULAR WEIGHT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SPLEEN; VIRUS RECOMBINANT; WESTERN BLOTTING; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHITOSAN; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; POLYESTERS;

EID: 82455209039     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.033     Document Type: Article

References (54)

1. Beigel J., Bray M. Current future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008, 78(1):91-102.
2. Louie J.K., Acosta M., Winter K., Jean C., Gavali S., Schechter R., et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. J Am Med Assoc 2009, 302(17):1896-1902.
3. Jamieson D.J., Honein M.A., Rasmussen S.A., Williams J.L., Swerdlow D.L., Biggerstaff M.S., et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009, 374(9688):451-458.
4. Anne Moscona M.D. Neuraminidase inhibitors for influenza. N Engl J Med 2005, 353(13):1363-1373.
5. Robert B., Couch M.D. Prevention and treatment of influenza. N Engl J Med 2000, 343(24):1778-1787.
6. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(16):1776-1779.
7. Hoskins T.W., Davies J.R., Smith A.J., Miller C.L., Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979, 1:33-35.
8. Patriarca P.A., Weber J.A., Parker R.A., Hall W.N., Kendal A.P., Bregman D.J., et al. Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985, 253:1136-1139.
9. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59:1-15.
10. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
11. Davis S.S. Nasal vaccines. Drug Deliv Rev 2001, 51:21-42.
12. Ugwoke M.I., Verbeke N., Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001, 53:3-21.
13. Ugwoke M.I., Agu R.U., Erbeke N., Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005, 57:1640-1665.
14. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12(5):387-400.
15. Frey A., Neutra M.R. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst Mitt 1997, 98:376-389.
16. Soane R.J., Ferier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive system in humans. Int J Pharm 1999, 178:55-65.
17. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003, 87:187-198.
18. Perez C., Castellanos I.J., Costantino H.R., Al-Azzam W., Griebenow K. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J Pharm Pharmacol 2002, 54:301-313.
19. Csaba N., Garcia-Fuentes M., Alonso M.J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv 2006, 3:463-478.
20. Clark M.A., Jepson M.A., Hirst B.H. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001, 50:81-106.
21. Issa M., Koping-Hoggard M., Artursson P. Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov Today: Technol 2005, 2:1-6.
22. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004, 274:1-33.
23. Haas J., Kumar M.N.R., Borchard G., Bakowsky U., Lehr C.M. Preparation and characterization of chitosan and trimethyl-chitosan-modified poly(e{open}-caprolactone) nanoparticles as DNA carriers. AAPS Pharm Sci Tech 2005, 6:E22-E30.
24. Benoit M.A., Baras B., Gillard J. Preparation and characterization of protein-loaded poly (epsilon-caprolactone) microparticles for oral vaccine delivery. Int J Pharm 1999, 184(1):73-84.
25. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006, 24:4201-4211.
26. Switzer R.C., Merril C.R., Shifrin S. A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels. Anal Biochem 1979, 98:231-237.
27. Gizurarson S. Animal models for intranasal drug delivery studies. A review article. Acta Pharm Nord 1990, 2:105-122.
28. Amorij J-P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25(35):6447-6457.
29. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 1998, 16:2069-2076.
30. de Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 2001, 19:2898-2907.
31. McCutcheon M., Wehner N., Wensky A., Kushner M., Doan S., Hsiao L., et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997, 210(2):149-166.
32. Singh M., Briones M., O'Hagan D.T. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001, 70:267-276.
33. Heydenreich A.V., Westmeier R., Pedersen N., Poulsen H.S., Kristensen H.G. Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity. Int J Pharm 2003, 254:83-87.
34. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999, 178:55-65.
35. Eyles J.E., Bramwell V.W., Williamson E.D., Alpar H.O. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 2001, 19:4732-4742.
36. Jenkins P.G., Coombes A.G., Yeh M.K., Thomas N.W., Davis S.S. Aspects of the design and delivery of microparticles for vaccine applications. J Drug Target 1995, 3:79-81.
37. Coombes A.G., Lavelle E.C., Jenkins P.G., Davis S.S. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996, 14:1429-1438.
38. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(d,llactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002, 60:480-486.
39. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21:1250-1255.
40. Hovden A.O., Cox R.J., Madhun A., Haaheim L.R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 2005, 62:342-352.
41. Van Der Lubben I.M., Verhoef J.C., Fretz M.M., Van Opdorp F.A.C., Mesu I., Kersten G., et al. Trimethyl chitosan chloride (TMC) as novel excipient for oral and nasal immunization against diphtheria. STP Pharm Sci 2002, 12:235-242.
42. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994, 11:1358-1361.
43. Borchard G., Luessen H.L., de Boer A.G., Verhoef J.C., Lehr C.M., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption and effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 1996, 39:131-138.
44. Di Colo G., Burgalassi S., Zambito Y., Monti D., Chetoni P. Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxacin transcorneal permeation. J Pharm Sci 2004, 93:2851-2862.
45. Pan Y., Li Y.J., Zhao H.Y., Zheng J.M., Xu H., Wei G., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002, 249:139-147.
46. Coutelier J.P., van der Logt J.T., Heessen F.W.A., Warnier G., van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987, 165:64-69.
47. Hocart M.J., Mackenzie J.S., Stewart G.A. The IgG subclass responses to influenza virus haemagglutinin in the mouse: effect of route of inoculation. J Gen Virol 1989, 70:809-818.
48. McNabb P.C., Tomasi T.B. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 1981, 35:477-496.
49. Renegar K.B., Small P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 1991, 146:1972-1978.
50. Kiyono H., Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4:699-710.
51. Bienenstock J., McDermott M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005, 206:22-31.
52. McDermott M.R., Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 1979, 122(5):1892-1898.
53. Smith D.J., Bot S., Dellamary L., Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003, 21(21-22):2805-2812.
54. Swain S.L., Agrewala J.N., Brown D.M., Jelley-Gibbs D.M., Golech S., Huston G., et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 2006, 211:8-22.